BiotechTube

MGL-3196 + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NASH - Nonalcoholic Steatohepatitis

Conditions

NASH - Nonalcoholic Steatohepatitis

Trial Timeline

Mar 28, 2019 → Jan 1, 2028

NCT ID
NCT03900429

About MGL-3196 + Placebo

MGL-3196 + Placebo is a phase 3 stage product being developed by Madrigal Pharmaceuticals for NASH - Nonalcoholic Steatohepatitis. The current trial status is active. This product is registered under clinical trial identifier NCT03900429. Target conditions include NASH - Nonalcoholic Steatohepatitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT03900429Phase 3Active
NCT02912260Phase 2Completed

Competing Products

20 competing products in NASH - Nonalcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
AZD2693AstraZenecaPhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
LIK066 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
52
Tropifexor + LicogliflozinNovartisPhase 2
52
LMB763 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + PlaceboNovartisPhase 2
52
TRO19622 + PlaceboRochePhase 2
52
SEL + SIMGilead SciencesPhase 2
51
Seladelpar + PlacebosGilead SciencesPhase 2
51
Placebo + SIMGilead SciencesPhase 2
51
CilofexorGilead SciencesPhase 1
32
Firsocostat + FenofibrateGilead SciencesPhase 1
32

Other Products from Madrigal Pharmaceuticals

Placebo + ResmetiromPhase 3
74
ResmetiromPhase 3
74
Resmetirom + PlaceboPhase 3
74
Resmetirom + PlaceboPhase 2
49
MGL-3196 (resmetirom) + PlaceboPhase 2
49